600 related articles for article (PubMed ID: 32214795)
1. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
[TBL] [Abstract][Full Text] [Related]
2. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Structural Elucidation of Novel Benzothiazole Derivatives as Anti-tubercular Agents: In-silico Screening for Possible Target Identification.
Venugopala KN; Chandrashekharappa S; Pillay M; Bhandary S; Kandeel M; Mahomoodally FM; Morsy MA; Chopra D; Aldhubiab BE; Attimarad M; Alwassil OI; Harsha S; Mlisana K; Odhav B
Med Chem; 2019; 15(3):311-326. PubMed ID: 29968540
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
5. 1-(Piperidin-3-yl)thymine amides as inhibitors of
Jian Y; Risseeuw MDP; Froeyen M; Song L; Cappoen D; Cos P; Munier-Lehmann H; van Calenbergh S
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1730-1739. PubMed ID: 31822127
[TBL] [Abstract][Full Text] [Related]
6. Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors.
Song L; Merceron R; Hulpia F; Lucía A; Gracia B; Jian Y; Risseeuw MDP; Verstraelen T; Cos P; Aínsa JA; Boshoff HI; Munier-Lehmann H; Savvides SN; Van Calenbergh S
Eur J Med Chem; 2021 Dec; 225():113784. PubMed ID: 34450493
[TBL] [Abstract][Full Text] [Related]
7. Elaboration of a proprietary thymidylate kinase inhibitor motif towards anti-tuberculosis agents.
Song L; Risseeuw MDP; Froeyen M; Karalic I; Goeman J; Cappoen D; Van der Eycken J; Cos P; Munier-Lehmann H; Van Calenbergh S
Bioorg Med Chem; 2016 Nov; 24(21):5172-5182. PubMed ID: 27614917
[TBL] [Abstract][Full Text] [Related]
8. 5-Arylaminouracil Derivatives: New Inhibitors of Mycobacterium tuberculosis.
Matyugina E; Novikov M; Babkov D; Ozerov A; Chernousova L; Andreevskaya S; Smirnova T; Karpenko I; Chizhov A; Murthu P; Lutz S; Kochetkov S; Seley-Radtke KL; Khandazhinskaya AL
Chem Biol Drug Des; 2015 Dec; 86(6):1387-96. PubMed ID: 26061192
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and characterization of (1-(4-aryl)- 1H-1,2,3-triazol-4-yl)methyl, substituted phenyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylates against Mycobacterium tuberculosis.
Venugopala KN; Dharma Rao GB; Bhandary S; Pillay M; Chopra D; Aldhubiab BE; Attimarad M; Alwassil OI; Harsha S; Mlisana K
Drug Des Devel Ther; 2016; 10():2681-90. PubMed ID: 27601885
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure activity relationships of cyanopyridone based anti-tuberculosis agents.
Jian Y; Hulpia F; Risseeuw MDP; Forbes HE; Munier-Lehmann H; Caljon G; Boshoff HIM; Van Calenbergh S
Eur J Med Chem; 2020 Sep; 201():112450. PubMed ID: 32623208
[TBL] [Abstract][Full Text] [Related]
12.
Deb PK; Al-Shar'i NA; Venugopala KN; Pillay M; Borah P
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):869-884. PubMed ID: 34060396
[TBL] [Abstract][Full Text] [Related]
13. Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors.
Song L; Merceron R; Gracia B; Quintana AL; Risseeuw MDP; Hulpia F; Cos P; Aínsa JA; Munier-Lehmann H; Savvides SN; Van Calenbergh S
J Med Chem; 2018 Apr; 61(7):2753-2775. PubMed ID: 29510037
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
15. Novel thiomorpholine tethered isatin hydrazones as potential inhibitors of resistant Mycobacterium tuberculosis.
Karunanidhi S; Chandrasekaran B; Karpoormath R; Patel HM; Kayamba F; Merugu SR; Kumar V; Dhawan S; Kushwaha B; Mahlalela MC
Bioorg Chem; 2021 Oct; 115():105133. PubMed ID: 34329993
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel imidazo[1,2-a]pyridinecarboxamides as potent anti-tuberculosis agents.
Onajole OK; Lun S; Yun YJ; Langue DY; Jaskula-Dybka M; Flores A; Frazier E; Scurry AC; Zavala A; Arreola KR; Pierzchalski B; Ayitou AJ; Bishai WR
Chem Biol Drug Des; 2020 Dec; 96(6):1362-1371. PubMed ID: 32515129
[TBL] [Abstract][Full Text] [Related]
17. 2,4-Dialkyl-8,9,10,11-tetrahydrobenzo[g]pyrimido[4,5-c]isoquinoline-1,3,7,12(2H,4H)-tetraones as new leads against Mycobacterium tuberculosis.
Claes P; Cappoen D; Uythethofken C; Jacobs J; Mertens B; Mathys V; Verschaeve L; Huygen K; De Kimpe N
Eur J Med Chem; 2014 Apr; 77():409-21. PubMed ID: 24681334
[TBL] [Abstract][Full Text] [Related]
18. Drug design and identification of potent leads against mycobacterium tuberculosis thymidine monophosphate kinase.
Van Calenbergh S; Pochet S; Munier-Lehmann H
Curr Top Med Chem; 2012; 12(7):694-705. PubMed ID: 22283813
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
[TBL] [Abstract][Full Text] [Related]
20. Hybrid Design of Isonicotinic Acid Hydrazide Derivatives: Machine Learning Studies, Synthesis and Biological Evaluation of their Antituberculosis Activity.
Kovalishyn V; Hodyna D; Sinenko VO; Blagodatny V; Semenyuta I; Slivchuk SR; Brovarets V; Poda G; Metelytsia L
Curr Drug Discov Technol; 2020; 17(3):365-375. PubMed ID: 30973110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
